Discovery Matters

By: Discovery Matters
  • Summary

  • A collection of stories and insights on matters of discovery that advance life sciences. Brought to you by the curious people at Cytiva.
    195688
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • 95. Modality convergence in advanced therapies
    Oct 24 2024

    Join us as Dr. Aravind Asokan from Duke University explores cutting-edge technologies revolutionizing advanced therapies, including CRISPR, mRNA, viral vectors, and cell therapies. He shares key lessons from past challenges, discusses scalability, product quality, and how integrating various therapeutic approaches is shaping the future of disease treatment.

    This episode covers exciting advancements in AAV with CRISPR, CAR T cell therapy, circular RNA, and virus-like particles (VLPs).


    Show notes:

    Asokan A, et al. ‘An evolved AAV variant enables efficient genetic engineering of murine T cells’. Cell. 2023 Jan 19;186(2):446-460. https://doi.org/10.1016/j.cell.2022.12.022


    Show more Show less
    20 mins
  • 94. Discovery Maker: Dr Michael Houghton
    Oct 14 2024

    Dive into the fascinating world of virology as we welcome Nobel Prize-winning virologist Dr. Michael Houghton on this episode of Discovery Matters. We explore Dr. Houghton's groundbreaking work in identifying the hepatitis C virus (HCV) and his enduring quest to combat this global health threat.

    From the monumental discovery of HCV in 1982 to the revolutionary diagnostic tests that nearly eradicated transfusion-related hepatitis C by the mid-1990s, Dr. Houghton provides an engaging and insightful journey through decades of scientific innovation.

    Show notes

    • Richard D Roberts, Patrick C Kyllonen, ‘Morningness–eveningness and intelligence: early to bed, early to rise will likely make you anything but wise!’ Personality and Individual Differences, Volume 27, Issue 6, 1999. https://doi.org/10.1016/S0191-8869(99)00054-9.
    • Taquet, MaximeLone, Nazir et al. ‘Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK.’ The Lancet Psychiatry, Volume 11, Issue 9. https://doi.org/10.1016/S2215-0366(24)00214-1
    Show more Show less
    18 mins
  • 93. How sustainable is biopharma?
    Sep 26 2024

    Eco-design, collaboration, circular economy. These are the bywords of sustainability in biopharma.

    Join Ryan Walker, Senior Director of Sustainability at Cytiva, and Aude Arkham, Global Head of Eco Design and Circular Economy at Sanofi, as they explore how eco-design and circular economy initiatives are shaping the future of healthcare.

    We delve into challenges, achievements, and the transformational potential of sustainability efforts within biopharma. From Sanofi’s life cycle assessments to industry-wide data difficulties, this episode navigates the complex landscape of creating greener solutions without compromising innovation and compliance.

    Show more Show less
    27 mins

What listeners say about Discovery Matters

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.